<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10147">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974855</url>
  </required_header>
  <id_info>
    <org_study_id>B7841002</org_study_id>
    <secondary_id>2016-001885-27</secondary_id>
    <nct_id>NCT02974855</nct_id>
  </id_info>
  <brief_title>PF-06741086 Multiple Dose Study in Severe Hemophilia</brief_title>
  <official_title>A Multicenter, Open-label, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous And/or Intravenous Pf-06741086 In Subjects With Severe Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics,
      pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of
      PF-06741086 in subjects with severe hemophilia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Anticipated">November 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with laboratory abnormalities</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Following parameters were analyzed for laboratory examination: hematology, serum chemistry, and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with changes from baseline in vital signs</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Following parameters were analyzed for vital sign examination: blood pressure, pulse rate, temperature, respiration rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Following parameters were analyzed for ECG examinations: QT interval (QTc), QTcF interval (Fridericia's Correction), QRS complex, PR interval, and RR interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with changes from baseline in physical examination</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Following parameters were analyzed for full physical examinations: head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with infusion site reactions</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Following parameters were analyzed for injection site reaction examinations: induration, erythema, edema, rash, pruritis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with injection site reactions</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Following parameters were analyzed for injection site reaction examinations: induration, erythema, edema, rash, pruritis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Bleeding episodes requiring treatment with factor replacement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation (lag time)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation (peak thrombin generation)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation (maximum thrombin generation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation (endogenous thrombin generation potential)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation (area under the thrombin generation curve).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin fragment 1+2</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dilute prothrombin time</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total TFPI</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Total amount of tissue factor pathway inhibitor (bound and unbound) in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti drug antibody (ADA) and neutralizing antibody (NAb) production against PF 06741086</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>The percentage of participants with positive ADA and neutralizing antibodies will be summarized for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-06741086 concentrations</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Plasma PF-06741086 concentrations over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Cmax (Tmax)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to last quantifiable concentration (AUClast)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Area under the curve from time zero to last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t 1/2)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations (Ctrough)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Minimum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state. IV administration only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Clearance is a quantitative measure of the rate at which a drug substance is removed from the body. IV administration only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Apparent clearance is a quantitative measure of the rate at which a drug substance is removed from the body.SC administration only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations at steady state (Css)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Plasma concentrations at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for steady state (Tss)</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Time to reach steady state plasma concentrations</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia A or B</condition>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 subcutaneous (SC) injection</description>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 SC injection</description>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 SC injection</description>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 intravenous (IV) infusion</description>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A or B (Factor VIII or Factor IX activity â‰¤ 1%) with no known
             Factor VIII or Factor IX inhibitors

          -  Episodic (on-demand) treatment regimen prior to screening

          -  At least 6 acute bleeding episodes during the 6-month period prior to screening

        Exclusion Criteria:

          -  Known coronary artery, thrombotic, or ischemic disease

          -  Detectable or documented history of inhibitors against Factor VIII or Factor IX
             during the 12-month period prior to screening

          -  Concomitant treatment with rFVIIa or activated prothrombin complex concentrate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Dr. Sotero del Rio</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz. Servicio de Farmacia - Drug Shipment Only</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7841002&amp;StudyName=A+Multicenter%2C+Open-label%2C+Multiple+Ascending+Dose+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+Pharmacodynamics%2C+And+Efficacy+Of+Subcutaneous+And%2For+Intravenous+Pf-06741086+In+Subjects+With+Severe+Hemophilia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>November 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
